Japan plans to revise its definition of “vaccines of high development priority.” The Ministry of Health, Labor and Welfare’s (MHLW)…
REGULATORY
New Price Cut Scheme for Off-Patent Meds Proposed with Mitigation Plans, but Payer Reps Say Gx Transition Too Slow: Chuikyo
The Ministry of Health, Labor and Welfare (MHLW) on November 22 proposed a new price revision scheme for off-patent brand name drugs called long-listed products (LLPs), which would basically bring down the NHI prices of LLPs to 2.5 times the…
To read the full story
Related Article
- Single Price Band Rule for Generics to Get Underway in April 2020: MHLW
December 22, 2017
- MHLW Proposes Pricing Support for Startups: Chuikyo
November 28, 2017
- MHLW Unveils Gx Pricing Plans, Wants to Rectify Distortion by Cutting Oral AG Price: Chuikyo
November 28, 2017
- CEA-Based Price Tweak Likely to Cover Premium Portion, Not Total Price; Price Raise Also Proposed: Chuikyo
November 28, 2017
- MHLW Proposes Expansion of “Essential Drug” Category to Include Crude Drugs, Ointment Bases, Local Dental Anesthetics and More: Chuikyo
November 28, 2017
- MHLW Proposes Tacking Premiums on Total Drug Price under Cost Calculation Formula: Chuikyo
November 27, 2017
- Quarterly Market Expansion Re-Pricing Pitched for 35-Plus Billion Yen Products: Chuikyo
November 24, 2017
- MHLW Proposes Post-Launch Foreign Price Adjustments: Chuikyo
November 24, 2017
- Draft Outline of Drug Pricing Overhaul Unveiled at Chuikyo; De-Facto Shrinkage for Price Maintenance Scheme Proposed
November 24, 2017
- Chuikyo Agrees to Define Scope of Off-Year Re-Pricing by 2020-End for 1st Off-Year Revision in April 2021
November 22, 2017
REGULATORY
- FPMAJ Reports Detailed Results of Blanket Self-Inspections for Generic Firms
January 29, 2025
- Celltrion Is Developer of Japan’s Third Stelara Biosimilar in the Wings
January 29, 2025
- MHLW Donates Mpox Vaccine to Congo
January 28, 2025
- LDP-OK’ed Bill for PMD Act Amendment Specifies Launch of Innovative Drug Fund
January 28, 2025
- Opposition Party Member Calls for Chuikyo Reform
January 27, 2025
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…